ID   MCF-7/mu-p53
AC   CVCL_E3DM
RX   PubMed=7712469;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; 11998; TP53 (Note=With p.Ala143Val).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   PubMed=7712469;
RA   Fan S.-J., Smith M.L., Rivet D.J. 2nd, Duba D.E., Zhan Q.-M., Kohn K.W.,
RA   Fornace A.J. Jr., O'Connor P.M.;
RT   "Disruption of p53 function sensitizes breast cancer MCF-7 cells to
RT   cisplatin and pentoxifylline.";
RL   Cancer Res. 55:1649-1654(1995).
//